Closing Bell: Rare earths hit launches 300pc small cap moon shot as ASX benchmark beards its bears
Closing Bell: Rare earths hit launches 300pc small cap moon shot, as ASX benchmark beards its bears
Source: stockhead.com.au
Dimerix Ltd News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Dimerix Ltd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Dimerix Ltd Today - Breaking & Trending Today
Dimerix with Proactive at ASX Small and Mid Cap Conference
Dimerix Ltd (ASX:DXB, OTC:SBMJF) CEO and managing director Nina Webster chats with Proactive live from the ASX Small and Mid Cap Conference in March 2024....
Source: proactiveinvestors.com
Dimerix raises AU$20M on positive phase III kidney disease data
Dimerix Ltd. announced a AU$20 million ($US13.22 million) capital raise following the news that its lead candidate, DMX-200, was successful in a prespecified interim analysis of the efficacy endpoint in its pivotal phase III trial in focal segmental glomerulosclerosis, a rare kidney disease.
Source: bioworld.com
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Market Foresees Noteworthy US$4.89 Billion Va
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics MarketThe global focal segmentmental glomerulosclerosis (FSGS) treatments market sales is expected to expand at a compound annual growth rate (CAGR) of 5% between 2023 and 2033, from US$ 3 billion in 2023 to US$ 4.89 billion by 2033. From 2018 to 2022, Focal Seg...
Source: pharmiweb.com
Dimerix at the Australian Microcap Investment Conference
Dimerix Ltd (ASX:DXB, OTC:SBMJF) CEO Dr Nina Webster speaks with Proactive ahead of the Australian Microcap Investment Conference in Melbourne. Dimerix is a...
Source: proactiveinvestors.com